Current Guidelines for the Management of Branch Duct Intraductal Papillary Mucinous Neoplasms

Brian KP Goh*1,2*

1Department of Hepatobiliary and Transplantation Surgery, Singapore General Hospital, Singapore
2Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore

The management of pancreatic cystic neoplasms has been constantly evolving and changing over the past 2 decades [1-3]. This is mainly due to the rapid advancement of knowledge in this field resulting in particular: 1) the improved understanding of the natural history and biological behavior of the different pathological entities which comprise pancreatic cystic neoplasms and 2) more accurate preoperative diagnosis of these neoplasms as a result of a better understanding of their individual morphological characteristics on imaging and the introduction of newer diagnostic modalities such as endoscopic ultrasonography with fine needle aspirate (EUS-FNA) [2-4]. In general, the management approach has trended from that of aggressive surgical resection [5] to a more selective approach whereby most cystic neoplasms are now managed via surveillance [1,6-8].

Since the landmark paper by Compagno and Oertel [9]; the general consensus was that all mucinous neoplasms were potentially malignant or malignant and should be surgically resected whereas serous cystic neoplasms were benign and could be managed conservatively [2,10,11]. Subsequently, investigators recognized that mucinous neoplasms were actually composed of 2 distinct pathological entities i.e. mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) [10,12,13]. More recently, it was recognized that IPMNs could be classified into branch-duct (BD), main-duct (MD) and mixed-duct types (MT) [14,15]. BD-IPMNs were found to be associated with a less aggressive biological behavior when compared to MD/MT-IPMN and many investigators have since demonstrated that selected BD-IPMNs could be managed conservatively [1,6,8,14,16].

In 2006, an international panel of experts formulated the Sendai Consensus Guidelines (SCG) to guide the management of IPMNs and MCNs [2,14]. According to these guidelines, all MD/MT-IPMNs and MCNs should be resected whereas selected BD-IPMNs without ‘suspicious features’ (SCG-ve) could be observed [2,14]. The suspicious features were cyst size >3 cm, presence of symptoms, dilated main pancreatic duct (>6 mm), presence of solid component and/or a positive cyst fluid cytology [2,14]. The SCG has since been validated by several studies [2,6,7]. It is widely recognized that the main limitation of the SCG is its low positive predictive value (PPV) resulting in resection of many benign BD-IPMNs [2,15,17]. However, the safety of the SCG has been confirmed by several large studies which have reported a high Negative Predictive Value (NPV) of 86% to 100% [2,17]. Even more importantly, all of the malignant lesions missed in most of these studies were IPMNs with high grade dysplasia and none had invasive carcinoma [2,17]. We recently performed a systematic review of studies validating the SCG for BD-IPMN which confirmed that the SCG was associated with a low PPV but high NPV (personal communication). Pooled analysis of 10 studies demonstrated that the PPV of SCG-ve BD-IPMNs was 34% and 26 of 242 (11%) resected SCG-ve BD-IPMNs were malignant (11 invasive). However, it was important to note that of the 18 patients including all 11 invasive BD-IPMNs were from a single study from Germany [8,17]. More recent results from the Memorial Sloan-Kettering Cancer Center reported 5 (14%) HGD among 35 resected SCG -ve BD-IPMN [18] whereas the Massachusetts General Hospital reported a 6.5% risk of HGD among 46 SCG -ve BD-IPMN smaller than 3 cm based on the revised 2012 SCG [6,17]. Importantly, unlike the German study; no invasive cancers were detected in both these studies among the SCG -ve neoplasms [17]. There are several possible reasons why data from the German study was contrary to that from data available from most other studies in the literature [17-19].

As many investigators recognized the limitations of the original SCG, the SCG was revised in Fukouka in 2010 and published recently in 2012 [2,7,14,15]. These revisions to the SCG were made to overcome its main limitation of its low PPV which resulted in a large number of benign BD-IPMNs being resected. The revised 2012 SCG classified BD-IPMNs into 3 categories (high risk, worrisome risk and low risk) instead of 2. According to these revised guidelines, some BD-IPMNs which would be classified as SCG+ve were now classified in the worrisome risk group and could potentially be observed after further evaluation by EUS-FNA [15]. The utility of these revised guidelines were validated by 2 recent studies [6,7].

Finally, it is imperative to remember that although both the SCG and the revised SCG are useful in guiding the management of IPMNs, guidelines are merely guidelines [17]. The limitations of these guidelines are they do not take into account important factors which would influence management such as a patient’s fitness for surgery, life expectancy, risk and type of surgery and even the cost of treatment or investigations [17]. The main consideration when deciding whether to surgically treat or observe a BD-IPMN should be to balance the risk of surgery versus the risk of the patient developing and dying from pancreatic malignancy [17]. For example, most would agree that the ideal treatment for an 85-year old with a 2 cm BD-IPMN in the head of pancreas with a normal sized main pancreatic duct would differ significantly from a 55-year old with a 2.8 cm BD-IPMN in the tail of pancreas associated with a 4 mm dilated main pancreatic duct although both would be considered low risk SCG lesions.

*Corresponding author: Brian KP Goh, Department of Hepatobiliary and Transplantation Surgery, Division of Surgery, Singapore General Hospital, 20 College Road, Academia Level 5, Singapore 169856, Tel: +65-63214051; Fax: +65-62206923; E-mail: sgkp@hotmail.com

Received January 03, 2014; Accepted January 06, 2014; Published January 13, 2014

Citation: Goh BKP (2014) Current Guidelines for the Management of Branch Duct Intraductal Papillary Mucinous Neoplasms. Pancreat Disord Ther 4: e134. doi:10.4172/2165-7092.1000e134

Copyright: © 2014 Goh BKP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
References


